InsidersTradesSigma
Follow the AtriCure, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, AtriCure, Inc. has recorded 235 insider filings. Market capitalisation: €2.5bn. The latest transaction was disclosed on 4 September 2026 (Cession). Among the most active insiders: CARREL MICHAEL H. The full history is openly available.
235
Insider Decl.
n/a
Thresholds
€104,822
2 ops.
Buy Volume
€12m
57 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate AtriCure, Inc. Buy (bullish), based on 9 analysts. Average price target: US$49.56.
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,579 of 29,062 companies
40.4
score / 100
Value39
Quality42
FCF yld1.7%
Earn yld-0.5%
EV/EBITDA·
ROE2.2%
Gross mgn75%
Net mgn-2.1%
Debt/EBITDA4.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations235 total
7,763 shares@ US$52.500.017% mcap19.1% of flowCommon StockSEC:0001336063-26-000006:0
9,370 shares@ US$48.890.018% mcap30.9% of flowCommon StockSEC:0001861996-26-000006:0
9,370 shares@ US$48.88910.018% mcap100.0% of flowCommonSEC144:0001950047-26-008582
3,564 shares@ US$38.800.0070% mcap21.2% of flowCommon StockSEC:0001566083-26-000006:0
3,500 shares@ US$38.420.0068% mcap24.5% of flowCommon StockSEC:0001796057-26-000010:0
3,564 shares@ US$39.000.0070% mcap27.1% of flowCommonSEC144:0001959173-26-005641
3,500 shares@ US$38.41940.0068% mcap100.0% of flowCommonSEC144:0001950047-26-007681
700 shares0Common StockSEC:0001230584-26-000008:0
4,000 shares0Common StockSEC:0001230584-26-000008:1
25,000 shares@ US$19.950.025% mcap21.8% of flowCommon StockSEC:0001205069-26-000005:0
6,000 shares@ US$38.880.012% mcap15.4% of flowCommon StockSEC:0001862458-26-000011:0
25,000 shares@ US$37.840.047% mcap41.4% of flowCommon StockSEC:0001205069-26-000005:1
6,182 shares@ US$38.800.012% mcap15.6% of flowCommon StockSEC:0001666600-26-000004:0
6,182 shares@ US$38.80330.013% mcap18.5% of flowCOMMONSEC144:0001000275-26-000095
25,000 shares@ US$38.57780.051% mcap100.0% of flowCommonSEC144:0001950047-26-007344
6,000 shares@ US$38.87980.012% mcap100.0% of flowCommonSEC144:0001950047-26-007345
636 sharesCommon StockSEC:0001230584-26-000006:0
636 sharesCommon StockSEC:0001336063-26-000004:0
527 sharesCommon StockSEC:0001565823-26-000006:0
636 sharesCommon StockSEC:0001861996-26-000004:0
636 sharesCommon StockSEC:0001862458-26-000008:0
3,000 shares@ US$28.650.0038% mcap22.8% of flowCommon StockSEC:0001566083-26-000004:0
5,000 shares@ US$29.8311.4% of flowCommon StockSEC:0001862458-26-000004:0
10,000 shares@ US$14.9914.7% of flowCommon StockSEC:0001571208-26-000002:0
5,000 shares0Common StockSEC:0001230584-26-000004:0
25 of 235 declarations
关于 AtriCure, Inc.
AtriCure, Inc. 是一家美国医疗设备公司，在纳斯达克上市，股票代码为 ATRC，总部位于美国俄亥俄州梅森。该公司专注于心房颤动 (Afib) 的外科治疗、左心耳 (LAA) 管理和术后疼痛控制。实际上，AtriCure 作为一家专业的心脏和胸外科特许经营商运营，向医院、心脏外科医生和治疗复杂心律失常和疼痛管理病例的护理团队销售产品。（[news.atricure.com](https://news.atricure.com/press-release?utm_source=openai)） AtriCure 成立于 2000 年，其核心临床理念明确：通过专用工具而非通用手术器械改善 Afib 手术和相关手术的结果。随着时间的推移，公司从核心消融技术扩展到 LAA 排除和冷冻镇痛，为开放式和微创手术创建了更广泛的产品组合。其定位反映了该公司作为一家利基医疗技术创新者，拥有强大的心脏病学特性和在围手术期疼痛管理领域不断扩大的足迹。（[ir.atricure.com](https://ir.atricure.com/news-releases/news-release-details/atricure-announces-us-launch-atriclipr-provtm-device?utm_source=openai)） AtriCure 的主要产品线包括消融系统、手术钳、LAA 排除装置和冷冻神经阻滞解决方案。在其心脏产品组合中，AtriClip 系列是 LAA 管理的关键特许产品，而 Isolator 和 EnCompass 平台支持外科消融工作流程。该公司还强调冷冻疼痛管理工具作为术后疼痛的非阿片类药物选择，包括在主要手术中的应用，其中疼痛控制和减少阿片类药物暴露是重要的临床目标。这种多元化但仍专注的产品组合有助于 AtriCure 满足同一手术室和专业客户群内的相邻需求。（[atricure.com](https://www.atricure.com/)） 从竞争角度来看，AtriCure 受益于其在相对集中的细分市场中作为公认的专家，在该市场中，临床证据、外科医生熟悉度和产品性能比广泛的产品目录更重要。公司强调指南支持的 LAA 排除以及 AtriClip FLEX-Mini、cryoSPHERE MAX 和 EnCompass 等新产品的持续采用，这些产品支持了最近的商业势头。在地理上，AtriCure 在美国和国际上销售，管理层在最近的报告期内提到了美国和全球的增长。（[ir.atricure.com](https://ir.atricure.com/news-releases/news-release-details/atricure-reports-fourth-quarter-2025-and-full-year-2025?utm_source=openai)） 最近的运营更新强调了增长状况。AtriCure 报告 2026 年第一季度全球收入为 141.2 million 美元，同比增长 14.3%，此前 2025 年全年收入为 534.5 million 美元，增长 14.9%。该公司还强调了新产品的采用，并于 2025 年底宣布了新型双能量平台的首批患者治疗。对于投资者而言，AtriCure 代表了纳斯达克上市的美国专业增长型医疗技术公司，受益于 Afib 治疗、中风风险降低和非阿片类药物疼痛管理方面的结构性需求。（[ir.atricure.com](https://ir.atricure.com/news-releases/news-release-details/atricure-reports-fourth-quarter-2025-and-full-year-2025?utm_source=openai)）
